Tracy Curley

4.1k total citations · 2 hit papers
51 papers, 3.3k citations indexed

About

Tracy Curley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tracy Curley has authored 51 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tracy Curley's work include Prostate Cancer Treatment and Research (36 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Treatment and Pharmacology (9 papers). Tracy Curley is often cited by papers focused on Prostate Cancer Treatment and Research (36 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Treatment and Pharmacology (9 papers). Tracy Curley collaborates with scholars based in United States, Spain and Canada. Tracy Curley's co-authors include Howard I. Scher, Paul A. Marks, Lawrence B. Schwartz, Judy H. Chiao, William K. Kelly, William P. Tong, Victoria M. Richon, Owen A. O’Connor, William Kevin Kelly and Lee M. Krug and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Tracy Curley

50 papers receiving 3.2k citations

Hit Papers

Phase I Study of an Oral Histone Deacetylase Inhibitor, S... 2003 2026 2010 2018 2005 2003 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
    2005 739 citations William Kevin Kelly, Lee M. Krug et al. Journal of Clinical Oncology profile →
  2. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
    2003 525 citations Tracy Curley, Lawrence B. Schwartz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tracy Curley United States 24 1.7k 1.3k 1.1k 395 366 51 3.3k
William K. Kelly United States 23 805 0.5× 1.5k 1.1× 1.0k 0.9× 503 1.3× 611 1.7× 50 2.7k
L. Rhoda Molife United Kingdom 25 1.3k 0.8× 1.5k 1.2× 1.3k 1.2× 680 1.7× 198 0.5× 73 3.0k
Michael Millward Australia 25 1.1k 0.7× 1.1k 0.9× 1.7k 1.6× 331 0.8× 331 0.9× 43 2.9k
Michael T. Schweizer United States 33 929 0.5× 2.2k 1.7× 1.1k 1.0× 746 1.9× 321 0.9× 144 3.1k
David R. Shalinsky United States 27 2.3k 1.3× 1.0k 0.8× 1.7k 1.5× 1.3k 3.2× 224 0.6× 52 4.3k
Vincenzo Damiano Italy 26 1.4k 0.8× 1.2k 0.9× 1.9k 1.7× 459 1.2× 185 0.5× 62 3.2k
Alexander Laird United States 32 2.7k 1.6× 1.2k 1.0× 1.7k 1.5× 745 1.9× 480 1.3× 97 4.9k
John C. Araujo United States 25 851 0.5× 1.4k 1.1× 1.1k 1.0× 567 1.4× 134 0.4× 89 2.5k
G. R. Hudes United States 27 1.3k 0.7× 1.4k 1.1× 1.1k 1.0× 759 1.9× 371 1.0× 69 2.7k
Harold Keer United States 21 1.3k 0.8× 1.2k 0.9× 627 0.6× 610 1.5× 170 0.5× 75 2.6k

Countries citing papers authored by Tracy Curley

Since Specialization
Citations

This map shows the geographic impact of Tracy Curley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracy Curley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracy Curley more than expected).

Fields of papers citing papers by Tracy Curley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracy Curley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracy Curley. The network helps show where Tracy Curley may publish in the future.

Co-authorship network of co-authors of Tracy Curley

This figure shows the co-authorship network connecting the top 25 collaborators of Tracy Curley. A scholar is included among the top collaborators of Tracy Curley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracy Curley. Tracy Curley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Slovin, Susan F., Karen E. Knudsen, Susan Halabi, et al.. (2023). Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 41(32). 5015–5024. 3 indexed citations
2.
Zhao, Jimmy L., Emmanuel S. Antonarakis, Heather H. Cheng, et al.. (2023). Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer. 130(1). 53–62. 13 indexed citations
3.
Crawford, E. David, Marc B. Garnick, Robert H. Eckel, et al.. (2023). A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group. Urology Practice. 11(1). 18–29. 2 indexed citations
4.
Graham, Laura, Kalyan Banda, Alba Torres, et al.. (2018). A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investigational New Drugs. 36(3). 458–467. 61 indexed citations
5.
Danila, Daniel C., Timothy M. Kuzel, Jeremy Cetnar, et al.. (2016). A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). e16507–e16507. 2 indexed citations
6.
Delacruz, A., et al.. (2015). Nursing Management of Patients With Castration-Resistant Prostate Cancer Undergoing Radium-223 Dichloride Treatment. Clinical journal of oncology nursing. 19(2). E31–E35. 1 indexed citations
7.
Iyer, Gopa, Michael J. Morris, Dana E. Rathkopf, et al.. (2011). A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology. 69(4). 1089–1097. 30 indexed citations
8.
Morris, Michael J., William Kevin Kelly, Susan F. Slovin, et al.. (2009). Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer. European Urology. 56(2). 237–244. 64 indexed citations
9.
Rathkopf, Dana E., Michael A. Carducci, Michael J. Morris, et al.. (2008). Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. Journal of Clinical Oncology. 26(18). 2959–2965. 22 indexed citations
10.
Krug, Lee M., Tracy Curley, Lawrence B. Schwartz, et al.. (2006). Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic Acid. Clinical Lung Cancer. 7(4). 257–261. 108 indexed citations
11.
Morris, Michael J., Òren Smaletz, David B. Solit, et al.. (2004). High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 100(9). 1868–1875. 30 indexed citations
12.
Galsky, Matthew D., Mario Eisenberger, William K. Kelly, et al.. (2004). Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). Journal of Clinical Oncology. 22(14_suppl). 4592–4592. 2 indexed citations
13.
Solit, David B., Michael J. Morris, Susan F. Slovin, et al.. (2003). Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 98(9). 1842–1848. 30 indexed citations
14.
Verbel, David, William Kevin Kelly, Òren Smaletz, et al.. (2003). Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 61(1). 142–144. 6 indexed citations
15.
Kelly, William K., et al.. (1995). Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.. Journal of Clinical Oncology. 13(9). 2208–2213. 81 indexed citations
16.
Ghossein, Ronald, Howard I. Scher, William L. Gerald, et al.. (1995). Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.. Journal of Clinical Oncology. 13(5). 1195–1200. 183 indexed citations
17.
Scher, Howard I., Nancy L. Geller, Tracy Curley, & Tao Yue. (1993). Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.. Journal of Clinical Oncology. 11(3). 400–407. 34 indexed citations
18.
Seidman, Andrew D., Howard I. Scher, Janice Gabrilove, et al.. (1993). Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.. Journal of Clinical Oncology. 11(3). 408–414. 85 indexed citations
19.
Scher, Howard I., H.W. Herr, William R. Fair, et al.. (1989). Neo‐adjuvant Chemotherapy for Invasive Bladder Cancer. Experience with the M‐VAC Regimen. British Journal of Urology. 64(3). 250–256. 85 indexed citations
20.
Zeléfsky, Michael J., et al.. (1989). Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: A comparison of single dose and fractionated regimens. International Journal of Radiation Oncology*Biology*Physics. 17(6). 1281–1285. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William K. Kelly Breakdown of academic impact, for papers by L. Rhoda Molife Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by David R. Shalinsky Breakdown of academic impact, for papers by Vincenzo Damiano Breakdown of academic impact, for papers by Alexander Laird Breakdown of academic impact, for papers by John C. Araujo Breakdown of academic impact, for papers by G. R. Hudes Breakdown of academic impact, for papers by Harold Keer
Rankless by CCL
2026